Pyoderma gangrenosum
Pyoderma gangrenosum nyaéta kasakit kulit radang anu langka, dimana pustula nyeri atawa nodul jadi borok anu ngembang sacara bertahap. Pyoderma gangrenosum teu tepa. Pangobatan bisa ngawengku kortikosteroid, cyclosporin, atawa antibodi monoklonal. Sanajan bisa mangaruhan jalma ti sagala umur, biasana kapangaruhan ku jalma umur 40‑50 taun.
☆ AI Dermatology — Free Service
Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Dina suku hiji jalma anu ngidap colitis ulcerative.
relevance score : -100.0%
ReferencesPyoderma gangrenosum nyaéta kaayaan kulit anu jarang, nu nyababkeun borok nyeri jeung ujung beureum atawa wungu. Ieu digolongkeun kana kasakit radang sarta mangrupa bagian ti grup anu disebut dermatoses neutrophilic. Anu ngabalukarkeun Pyoderma gangrenosum téh kompleks, ngalibatkeun masalah dina sistem kekebalan bawaan jeung adaptif dina jalma anu rawan sacara genetik. Ayeuna, panaliti geus fokus kana follicle bulu salaku titik awal poténsial kasakit.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum nyaéta kaayaan kulit anu jarang, tapi nyababkeun borok anu kacida nyerina. Sanaos sababna teu dipikanyaho, urang terang yén éta ngalibatkeun paningkatan kagiatan sél imun. Ngubaran panyakit ieu henteu gampang. Aya rupa‑rupa ubar anu ngirangan sistem imun atawa ngarobah kagiatanana. Salian ti éta, urang ogé museurkeun kana ngubaran tatu jeung ngatur nyeri. Corticosteroids jeung cyclosporine sering jadi pilihan utama, tapi akhir‑akhir ieu aya panalungtikan leuwih seueur ngeunaan pamakean terapi biologis sapertos inhibitor TNF‑α. Biologics ieu beuki dipikaresep, utamana pikeun penderita kaayaan radang séjén, sarta ayeuna dipaké dina tahap awal kasakit.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
